Literatura académica sobre el tema "Mtb Infection"
Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros
Consulte las listas temáticas de artículos, libros, tesis, actas de conferencias y otras fuentes académicas sobre el tema "Mtb Infection".
Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.
También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.
Artículos de revistas sobre el tema "Mtb Infection"
Dempsey, Laurie A. "CD153 combats Mtb infection". Nature Immunology 19, n.º 11 (17 de octubre de 2018): 1148. http://dx.doi.org/10.1038/s41590-018-0246-4.
Texto completoRosas Mejia, Oscar, Erin S. Gloag, Jianying Li, Marisa Ruane-Foster, Tiffany A. Claeys, Daniela Farkas, Shu-Hua Wang, Laszlo Farkas, Gang Xin y Richard T. Robinson. "Mice infected with Mycobacterium tuberculosis are resistant to acute disease caused by secondary infection with SARS-CoV-2". PLOS Pathogens 18, n.º 3 (24 de marzo de 2022): e1010093. http://dx.doi.org/10.1371/journal.ppat.1010093.
Texto completoOlive, Andrew J., Clare M. Smith, Christina E. Baer, Jörn Coers y Christopher M. Sassetti. "Mycobacterium tuberculosis Evasion of Guanylate Binding Protein-Mediated Host Defense in Mice Requires the ESX1 Secretion System". International Journal of Molecular Sciences 24, n.º 3 (2 de febrero de 2023): 2861. http://dx.doi.org/10.3390/ijms24032861.
Texto completoWong, Eileen A., Carolyn Kraus, Keith A. Reimann y JoAnne L. Flynn. "The role of IL-10 during early M. tuberculosis infection in a non-human primate model". Journal of Immunology 198, n.º 1_Supplement (1 de mayo de 2017): 123.5. http://dx.doi.org/10.4049/jimmunol.198.supp.123.5.
Texto completoKieswetter, Nathan S., Mumin Ozturk, Lerato Hlaka, Julius Ebua Chia, Ryan J. O. Nichol, Jasmine M. Cross, Leah M. C. McGee et al. "Intranasally administered S-MGB-364 displays antitubercular activity and modulates the host immune response to Mycobacterium tuberculosis infection". Journal of Antimicrobial Chemotherapy 77, n.º 4 (25 de enero de 2022): 1061–71. http://dx.doi.org/10.1093/jac/dkac001.
Texto completoWong, Kevin, James Nguyen, Lillie Blair, Marina Banjanin, Bunraj Grewal, Shane Bowman, Hailey Boyd et al. "Pathogenesis of Human Immunodeficiency Virus-Mycobacterium tuberculosis Co-Infection". Journal of Clinical Medicine 9, n.º 11 (6 de noviembre de 2020): 3575. http://dx.doi.org/10.3390/jcm9113575.
Texto completoBian, Yao, Shaobin Shang, Sharmila Shanmuganad, Sarah Siddiqui y Chyung-Ru Wang. "Qa-1b has antigen presentation and immunoregulatory roles during aerogenic Mycobacterium tuberculosis infection (P3296)". Journal of Immunology 190, n.º 1_Supplement (1 de mayo de 2013): 134.1. http://dx.doi.org/10.4049/jimmunol.190.supp.134.1.
Texto completoHe, Xianbao, Jared J. Eddy, Karen R. Jacobson, Andrew J. Henderson y Luis M. Agosto. "Enhanced Human Immunodeficiency Virus-1 Replication in CD4+ T Cells Derived From Individuals With Latent Mycobacterium tuberculosis Infection". Journal of Infectious Diseases 222, n.º 9 (16 de mayo de 2020): 1550–60. http://dx.doi.org/10.1093/infdis/jiaa257.
Texto completoMoriarty, Ryan V., Amy L. Ellis y Shelby L. O’Connor. "Monkeying around with MAIT Cells: Studying the Role of MAIT Cells in SIV and Mtb Co-Infection". Viruses 13, n.º 5 (8 de mayo de 2021): 863. http://dx.doi.org/10.3390/v13050863.
Texto completoNusbaum, Rebecca, Matthew Huante, Putri Sutjita, Veronica Calderon, Sudhamathi Vijayakumar, Judith Aronson, Robert Hunter et al. "HIV-1 promotes neutrophil infiltration and lung damage in humanized mice co-infected with Mycobacterium tuberculosis (HUM1P.266)". Journal of Immunology 194, n.º 1_Supplement (1 de mayo de 2015): 52.15. http://dx.doi.org/10.4049/jimmunol.194.supp.52.15.
Texto completoTesis sobre el tema "Mtb Infection"
Jones, Shelby-Sara Ann. "The role of Lymphoblastic leukemia 1 (Lyl1) in Mycobacterium tuberculosis (Mtb) infection". Doctoral thesis, Faculty of Health Sciences, 2021. http://hdl.handle.net/11427/33727.
Texto completoRothchild, Alissa Chen. "Antimicrobial Roles for iNKT Cells and GM-CSF in Mycobacterium Tuberculosis Infection". Thesis, Harvard University, 2014. http://dissertations.umi.com/gsas.harvard:11371.
Texto completoBenet, Garrabé Susana. "Impact of a SIGLEC1 null variant on the pathogenesis of HIV-1 and Mtb infection". Doctoral thesis, Universitat Autònoma de Barcelona, 2021. http://hdl.handle.net/10803/671930.
Texto completoLas células presentadoras de antígeno de linaje mieloide tienen la capacidad de responder a una infección de una manera rápida y eficiente coordinando respuestas inmunes innatas y adaptativas. Sin embargo, en el caso de la infección por el virus de la inmunodeficiencia humana de tipo 1 (VIH-1), estas células pueden contribuir en la patogénesis viral a través de la captura y la transmisión de partículas virales a las células diana, un proceso conocido como trans-infección. Este mecanismo depende de Siglec-1 (CD169), un receptor de membrana de las células mieloides que reconoce gangliósidos sialidados presentes en la membrana del virus. Para analizar in vivo la contribución de la trans-infección en la patogénesis del VIH-1, buscamos individuos SIGLEC1-deficientes e identificamos 85 individuos heterocigotos y 2 homocigotos para una variante de pérdida de función que suprime la expresión de Siglec-1. De manera relevante, las células de estos individuos carecían de la actividad de Siglec-1 en relación a la captura y la transmisión del VIH-1. A pesar de este fenotipo, no hemos observado diferencias prominentes con respecto a la susceptibilidad a la infección por VIH-1 ni a la progresión hacia el síndrome de inmunodeficiencia adquirida (SIDA) en los individuos portadores de esta variante de SIGLEC1. A pesar de ello, el análisis del efecto del truncamiento de Siglec-1 en la progresión a SIDA no resultó concluyente debido al tamaño limitado de la cohorte, la falta de una historia clínica completa con información sobre la fecha de seroconversión, la restricción de estudiar solamente períodos sin tratamiento y la co-infección con patógenos adicionales que podrían influenciar el fenotipo observado en la dirección opuesta a lo esperado. De hecho, esta última limitación nos llevó a investigar el efecto de la variante SIGLEC1-deficiente en las co-infecciones asociadas al VIH-1 y encontramos una asociación significativa entre esta variante y la diseminación extrapulmonar de Mycobacterium tuberculosis (Mtb) en dos cohortes clínicas que incluyen 6,256 individuos. Cuando analizamos la ausencia de Siglec-1 en un modelo murino, los ratones knockout para Siglec-1 presentaron una propagación local de bacterias en el pulmón y a pesar de tener una carga bacilar similar, desarrollaron lesiones más extensas en comparación con los ratones salvajes. Además, hemos demostrado que Siglec-1 es necesario para inducir la presentación de antígenos a través de la captura de vesículas extracelulares. Proponemos un modelo en el que la ausencia de Siglec-1 retrasa el inicio de una inmunidad que protege frente la micobacteria limitando el intercambio de antígenos mediante vesículas extracelulares, permitiendo así una propagación local de la micobacteria que incrementa el riesgo de una diseminación extrapulmonar. En resumen, a lo largo de esta tesis hemos explorado el concepto de antagonismo pleiotrópico en individuos co-infectados portadores de la variante SIGLEC1-deficiente, donde la alteración del control inmune de la micobacteria en ausencia de Siglec-1 podría influenciar el curso clínico de los individuos infectados por VIH-1, enmascarando así los beneficios esperados de esta variante en el retraso de la progresión a SIDA.
Antigen presenting cells of the myeloid lineage have the ability to respond rapidly and effectively to infection by coordinating innate and adaptive immune responses. However, in the case of human immunodeficiency virus type 1 (HIV-1) infection, these cells might contribute to viral pathogenesis through the capture and transmission of infectious viral particles to target cells, a process known as trans-infection. This mechanism depends on Siglec-1 (CD169), a myeloid-cell surface receptor that recognizes sialylated gangliosides present on the viral membrane. To dissect the contribution of trans-infection in HIV-1 pathogenesis in vivo, we searched for SIGLEC1 null individuals and identified 85 heterozygous and 2 homozygous people with a loss-of-function variant that abrogates Siglec-1 expression. Importantly, cells from these individuals were defective for Siglec-1 activity in HIV-1 capture and transmission. Despite this phenotype, we did not observe prominent differences on HIV-1 susceptibility nor progression to acquired immunodeficiency syndrome (AIDS) in individuals harboring the SIGLEC1 null variant. Nonetheless, analysis of the effect of Siglec-1 truncation on progression to AIDS was not conclusive due to the limited cohort size, the lack of complete clinical records such as the seroconversion date, the restriction to study only off-therapy periods, and the co-infection with additional pathogens that might influence the observed phenotype in the opposite direction from what was expected. As a matter of fact, the latest limitation prompted us to investigate the effect of the SIGLEC1 null variant in HIV-1 co-infections and we found a significant association between this variant and extrapulmonary dissemination of Mycobacterium tuberculosis (Mtb) in two clinical cohorts comprising 6,256 individuals. When we analyzed the absence of Siglec-1 in a murine model, local spread of bacteria within the lung was apparent in Mtb-infected Siglec-1 knockout mice which, despite having similar bacterial load, developed more extensive lesions compared to wild type mice. Moreover, we demonstrated that Siglec-1 is necessary to induce antigen presentation through extracellular vesicle uptake. We postulate that lack of Siglec-1 delays the onset of protective immunity against Mtb by limiting antigen exchange via extracellular vesicles, allowing for an early local spread of mycobacteria that increases the risk for extrapulmonary dissemination. Overall, through this thesis we have explored the concept of antagonistic pleiotropy in co-infected individuals harboring the SIGLEC1 null variant, where the impaired immune control of Mtb in the absence of Siglec-1 could influence the clinical course of HIV-1 infected individuals, thus masking the expected benefits of this variant on delaying AIDS progression.
Universitat Autònoma de Barcelona. Programa de Doctorat en Bioquímica, Biologia Molecular i Biomedicina
Thiel, Bonnie Arlene. "Bioinformatics approaches to studying immune processes associated with immunity to Mycobacterium tuberculosis infection in the lung and blood". Case Western Reserve University School of Graduate Studies / OhioLINK, 2021. http://rave.ohiolink.edu/etdc/view?acc_num=case1627247387242562.
Texto completoKativhu, Chido L. "PhoP-regulated genes contribute to Mycobacteria tuberculosis-induced burst size necrosis in macrophages". eScholarship@UMMS, 2021. https://escholarship.umassmed.edu/gsbs_diss/1120.
Texto completoHartman, Michelle L. "M.tb Killing by Macrophage Innate Immune Mechanisms: A Dissertation". eScholarship@UMMS, 2011. https://escholarship.umassmed.edu/gsbs_diss/606.
Texto completovanzolini, tania. "Development of new biological drugs for the treatment of fungal infections". Doctoral thesis, Urbino, 2021. http://hdl.handle.net/11576/2692691.
Texto completoIqbal, Salma. "Phenotypical and Functional Characterization of Polarized Human Macrophages". Thesis, Université d'Ottawa / University of Ottawa, 2015. http://hdl.handle.net/10393/32009.
Texto completoLe, Run Eva. "Nouvelles combinaisons de β-lactamines et inhibiteurs de β-lactamase : vers un nouveau traitement des infections à Mycobacterium abscessus chez les patients atteints de mucoviscidose". Electronic Thesis or Diss., Sorbonne université, 2019. https://accesdistant.sorbonne-universite.fr/login?url=https://theses-intra.sorbonne-universite.fr/2019SORUS640.pdf.
Texto completoMycobacterium abscessus, a rapidly growing mycobacteria, is responsible for pulmonary infections in cystic fibrosis patients. The recommended treatment consists in an initial phase with the combination of a carbapenem (imipenem), a macrolide (azithromycin), an aminoglycoside (amikacin), and a glycylcycline (tigecycline). The team has investigated the optimization of treatments involving β-lactams and have demonstrated that avibactam, a 2nd generation β-lactamase inhibitor belonging to the diazabicyclooctane (DBO) family, inhibits the β-lactamase BlaMab produced by M. abscessus and substantially increases the efficacy of imipenem both in vitro, intracellularly, and in a zebrafish model. Expression of the β-lactamase gene was found to be induced in infected macrophages. The aim of my PhD project was to evaluate the efficacy of new β-lactam-β-lactamase inhibitor combinations and to investigate β-lactamase regulation in macrophages. In the first part of the thesis, new antibiotic combinations were evaluated in vitro and in macrophages infected by M. abscessus. Rifabutin, usually used in the treatment of infections due to other mycobacteria, showed synergistic activity with imipenem in vitro but the combination was not bactericidal. In infected macrophages, rifabutin enhanced the activity of imipenem and the addition of avibactam led to increased killing. Tedizolid, developed for the treatment of staphylococcal infections, displayed weak synergy in vitro but no bactericidal activity against M. abscessus. In macrophages, tedizolid enhanced the activity of imipenem and the imipenem-tedizolid-rifabutin-avibactam quadruple combination afforded 91% intracellular killing. Finally, the association of imipenem with relebactam, a new β-lactamase inhibitor developed in combination with imipenem, was found to be as active as the imipenem-avibactam both in vitro and in macrophage model. The second part of the thesis was focused on the identification of the stressor triggering the induction of β-lactamase production in macrophages. M. abscessus was grown in vitro in different culture media mimicking stress conditions thought to prevail in macrophages. The β-lactamase specific activity was determined using a chromogenic β-lactam (nitrocefin) as the substrate. None of the physicochemical conditions that were tested led to induction, including acidic pH, high concentrations of metals, oxidative stress or β-lactams. The last objective was to study the impact of the N versus G polymorphism located in the conserved SDN motif of mycobacterial β-lactamases on activity of β-lactam-β-lactamase inhibitor combinations. BlaMab from M. abscessus contains motif SDN whereas BlaC from M. tuberculosis contains motif SDG, a polymorphism that determines efficacious inhibition by either avibactam of clavulanate, respectively. Two isogenic strains of M. abscessus were constructed by allelic exchange. In comparison to the wild-type enzyme, the strain producing BlaMab with the N to G substitution was less susceptible to the β-lactam-avibactam combinations but more efficaciously inhibited by combinations comprising clavulanate. In the context of BlaC, the G to N substitution potentiated inhibition by avibactam. These results establish that the SDN/SDG polymorphism determines the efficacy of combinations comprising a β-lactam and avibactam or clavulanate, as expected from previous kinetic studies performed with purified β-lactamases. N to G and G to N substitutions might be mechanisms of resistance acquisition in M. abscessus and M. tuberculosis, respectively
Chakraborti, Srinjoy. "Therapeutic Antibody Against Neisseria gonorrhoeae Lipooligosaccharide, a Phase-variable Virulence Factor". eScholarship@UMMS, 2017. https://escholarship.umassmed.edu/gsbs_diss/905.
Texto completoLibros sobre el tema "Mtb Infection"
Matthews, Philippa C. Infections caused by mycobacteria. Editado por Philippa C. Matthews. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780198737773.003.0003.
Texto completoIsaacs, John D. y Philip M. Brown. Rituximab and abatacept. Oxford University Press, 2013. http://dx.doi.org/10.1093/med/9780199642489.003.0083.
Texto completoCapítulos de libros sobre el tema "Mtb Infection"
Li, Huoming y Hao Li. "Animal Models of Tuberculosis". En Vaccines for Neglected Pathogens: Strategies, Achievements and Challenges, 139–70. Cham: Springer International Publishing, 2023. http://dx.doi.org/10.1007/978-3-031-24355-4_7.
Texto completoGarhyan, Jaishree, Bikul Das y Rakesh Bhatnagar. "Mesenchymal Stem Cells: A Hidden Arsenal for Mtb Persistence, Resuscitation, and Reactivation". En Mycobacterium Tuberculosis: Molecular Infection Biology, Pathogenesis, Diagnostics and New Interventions, 301–14. Singapore: Springer Singapore, 2019. http://dx.doi.org/10.1007/978-981-32-9413-4_17.
Texto completoPeralta Alvarez, Marco Polo, Julia L. Marshall y Rachel Tanner. "Correlates of Protection from Tuberculosis". En Vaccines for Neglected Pathogens: Strategies, Achievements and Challenges, 99–137. Cham: Springer International Publishing, 2023. http://dx.doi.org/10.1007/978-3-031-24355-4_6.
Texto completoSingh, Yadvir. "Comparative In Silico Analyses Reveal Crucial Factors for Virulence, Antigenicity, and Evolution in M.tb". En Mycobacterium Tuberculosis: Molecular Infection Biology, Pathogenesis, Diagnostics and New Interventions, 171–88. Singapore: Springer Singapore, 2019. http://dx.doi.org/10.1007/978-981-32-9413-4_10.
Texto completoKumar Barik, Sushanta y Jyotirmayee Turuk. "Role of Exosomes in Tuberculosis: Looking Towards a Future Road Map". En Exosomes - Recent Advances From Bench to Bedside [Working Title]. IntechOpen, 2023. http://dx.doi.org/10.5772/intechopen.111544.
Texto completoBartlett, John G., Robert R. Redfield y Paul A. Pham. "Prevention of HIV and Prevention of Infection in PLWH". En Bartlett's Medical Management of HIV Infection, 107–74. Oxford University Press, 2019. http://dx.doi.org/10.1093/med/9780190924775.003.0003.
Texto completoChen, Bor-Sen. "Genetic-and-epigenetic host/pathogen networks for cross-talk mechanisms in human macrophages and dendritic cells during Mtb infection". En Systems Immunology and Infection Microbiology, 339–74. Elsevier, 2021. http://dx.doi.org/10.1016/b978-0-12-816983-4.00010-9.
Texto completoTiberi, Simon. "Tuberculosis and Other Mycobacterial Infections". En Tutorial Topics in Infection for the Combined Infection Training Programme. Oxford University Press, 2019. http://dx.doi.org/10.1093/oso/9780198801740.003.0035.
Texto completoDian Novita, Bernadette, Ari Christy Mulyono y Ferdinand Erwin. "Metformin for Tuberculosis Infection". En Metformin - Pharmacology and Drug Interactions. IntechOpen, 2021. http://dx.doi.org/10.5772/intechopen.99794.
Texto completoKaewphinit, Thongchai, Somchai Santiwatanakul y Kosum Chansiri. "The Detection of Tuberculosis by Loop-Mediated Isothermal Amplification (LAMP) Combined with a Lateral Flow Dipstick". En Handbook of Research on Diverse Applications of Nanotechnology in Biomedicine, Chemistry, and Engineering, 269–300. IGI Global, 2015. http://dx.doi.org/10.4018/978-1-4666-6363-3.ch013.
Texto completoActas de conferencias sobre el tema "Mtb Infection"
Todorova, Yana, Radoslava Emilova, Vladimir Milanov, Elizabeta Bachiyska, Yuliana Atanasova, Ana Baykova y Maria Nikolova. "Associations between lipid mediators and cytokine production at different stages of MTB infection". En ERS International Congress 2021 abstracts. European Respiratory Society, 2021. http://dx.doi.org/10.1183/13993003.congress-2021.pa2463.
Texto completoSilva, Jallysson Santos, CAIO ARAUJO DA CUNHA, DENNIS MIGUEL LEMOS DA SILVA y STEFAN VILGES DE OLIVEIRA. "ANÁLISE EPIDEMIOLÓGICA E PROPOSTA DE INTERVENÇÃO PARA OS CASOS DE TUBERCULOSE EM UBERLÂNDIA-MG". En I Congresso Brasileiro de Estudos Epidemiológicos On-line. Revista Multidisciplinar em Saúde, 2022. http://dx.doi.org/10.51161/epidemion/7130.
Texto completoEremeeva, Natalya, Tatyana Tyulkova, Leonid Lavrechuk, Ksenia Belousova, Tatyana Umpeleva y Diana Vakhrusheva. "Features of development of TB infection caused by different doses of MBT". En ERS International Congress 2018 abstracts. European Respiratory Society, 2018. http://dx.doi.org/10.1183/13993003.congress-2018.pa4732.
Texto completoMillman, Alexander J., David Dowdy, Robert Brownell, Adithya Cattamanchi y John L. Davis. "Cost-Benefit Analysis Of GeneXpert MTB/RIF For Evaluation Of Infectious Tuberculosis At An Urban Public Hospital". En American Thoracic Society 2012 International Conference, May 18-23, 2012 • San Francisco, California. American Thoracic Society, 2012. http://dx.doi.org/10.1164/ajrccm-conference.2012.185.1_meetingabstracts.a6505.
Texto completoBalasaniantc, Goar, Vladimir Galkin, Zinaida Zagdyn y Peter Yablonskii. "Tuberculosis and HIV infection in combination with multidrug resistant MBT on Northwest of Russia". En ERS International Congress 2016 abstracts. European Respiratory Society, 2016. http://dx.doi.org/10.1183/13993003.congress-2016.pa4262.
Texto completoBalasaniantc, Goar. "Bedaquiline in treatment of TB/HIV co-infection patients with extremely-drug resistance of MBT". En ERS International Congress 2018 abstracts. European Respiratory Society, 2018. http://dx.doi.org/10.1183/13993003.congress-2018.pa4742.
Texto completoGosal, Eshrina, Amanda Goodwin, Vidya Navaratnam, Lois Dexter y Anna L. Rich. "Routine liver function test monitoring of patients treated for active M.TB infection does not influence management: A real-world retrospective study". En ERS International Congress 2018 abstracts. European Respiratory Society, 2018. http://dx.doi.org/10.1183/13993003.congress-2018.pa2684.
Texto completo